German speciality chemicals company Evonik plans further investment in its Biotech branch: The production of bio–based amino acids for animal feed shall be boosted with some €350 million by 2014, company speakers explained.
Essen/Germany – “Biotech opens up interesting opportunities for profitable growth in a range of business areas,” says Patrik Wohlhauser, a member of the Executive Board. “In the Health & Nutrition Business Unit alone we are hoping for sales of €1 billion over the medium term for products made using biotechnology.” The company has announced investments of some €350 million in the production of its Biolys business by 2014. Biolys, an amino acid used for animal feed, is a source of L-lysine produced via fermentation.
Investments include construction of new L-lysine plants in Brazil and Russia capable of producing nearly 200,000 metric tons each year as well as a recently finished production expansion to 280,000 metric tons per year at its Blair site in North America.
Company Celebrates 30 Years in Biotechnologies
These announcements just coincidence with the 30th anniversary of Evonik's biotech research site at Halle–Kuensebeck, Germany: Here, Evonik researches on the potential of amino acids for feedstock and polymer productions. Dr. Peter Nagler, Chief Innovation Officer at Evonik, says: “Besides serving as an important part of the biotech platform of the entire company, Halle-Künsebeck is also closely linked to our strategic research in Marl, Germany. In Halle-Kuensebeck we concentrate our expertise in designing industrial-scale fermentation processes.”